Guide for Current and Future Residents
Counting down for 3rd Years: 2012-7-1 05:00:00 GMT+00:00!
Counting down for 2nd Years : 2013-7-1 05:00:00 GMT+00:00!
Counting down for 1st Years: 2014-7-1 05:00:00 GMT+00:00!
|
|
Spectrum of Activity |
Recommended Monitoring |
Effect on CYP450 |
Medication
PartialGTCAbsenceLGSISCBCLFTChem 7OtherInducerInhibitorMinorCarbamazepine (Tegretol)
++*++*Worsens√√√Level; If Asian, HLA-B*1502 before starting √Oxcarbazepine (Trileptal)
++*++#√√Valproic acid (Depakote)^
+++*+*++√√Level√Lamotrigine (Lamictal)^
++#++*+#++√Levetiracetam (Keppra)^
++#+#+#+Topiramate (Topamax)^++#++*+#+√Level, Eye exams√Zonisamide (Zonegran)^
++#+#++√Phenobarbital
++++√Level;
25-OHD (vitamin D)√Rufinamide (Banzel)^++Phenytoin (Dilantin)
++++√Level;
25-OHD (vitamin D)√Ethosuximide (Zarontin)
++*√√LevelVigabatrin (Sabril)
++++√Eye exam every 3 monthsLacosamide (Vimpat)++Tiagabine (Gabitril)++√√√Gabapentin/Pregabalin+Felbamate
++++++√√Monthly, significant risk for toxicity√√^ Considered broad-spectrum *Recommended first line # Recommended second line
Overview of Antiepileptic Medications
Michelle Condren, Pharm.D.
|
|
Spectrum of Activity |
Recommended Monitoring |
Effect on CYP450 |
Medication
PartialGTCAbsenceLGSISCBCLFTChem 7OtherInducerInhibitorMinorCarbamazepine (Tegretol)
++*++*Worsens√√√Level; If Asian, HLA-B*1502 before starting √Oxcarbazepine (Trileptal)
++*++#√√Valproic acid (Depakote)^
+++*+*++√√Level√Lamotrigine (Lamictal)^
++#++*+#++√Levetiracetam (Keppra)^
++#+#+#+Topiramate (Topamax)^++#++*+#+√Level, Eye exams√Zonisamide (Zonegran)^
++#+#++√Phenobarbital
++++√Level;
25-OHD (vitamin D)√Rufinamide (Banzel)^++Phenytoin (Dilantin)
++++√Level;
25-OHD (vitamin D)√Ethosuximide (Zarontin)
++*√√LevelVigabatrin (Sabril)
++++√Eye exam every 3 monthsLacosamide (Vimpat)++Tiagabine (Gabitril)++√√√Gabapentin/Pregabalin+Felbamate
++++++√√Monthly, significant risk for toxicity√√^ Considered broad-spectrum *Recommended first line # Recommended second line
Overview of Antiepileptic Medications
Michelle Condren, Pharm.D.